Bayer to spend $20m to correct misleading advertising for oral contraceptive Yaz
18 februari 2009
Bayer Healthcare Pharmaceuticals has agreed to spend $20m (£14m; €15.6m) to correct misleading direct to consumer advertising of its birth control pill Yaz (drospirenone and ethinylestradiol), the most popular birth control pill in the United States, with sales of about $616m last year.
Bron: BMJ (registratie verplicht); zie ook The New York Times en de waarschuwingsbrief van de FDA (pdf)
| < Vorige | Volgende > |
|---|
